Literature DB >> 2519892

Direct evidence of elevated levels of circulating platelet-activating factor in a patient with disseminated intravascular coagulation syndrome.

K Sakaguchi1, F Masugi, Y H Chen, M Inoue, T Ogihara, K Yamada, I Yamatsu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2519892

Source DB:  PubMed          Journal:  J Lipid Mediat        ISSN： 0921-8319


× No keyword cloud information.
  4 in total

1.  Effect of a selective PAF antagonist SM-10661 ((+/-)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one HCl) on experimental disseminated intravascular coagulation (DIC).

Authors:  N Imanishi; Y Komuro; S Morooka
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

2.  Failure of the platelet-activating-factor antagonist WEB 2086 BS for treatment of chronic autoimmune thrombocytopenia.

Authors:  G Giers; H Janzarik; E R Kempe; C Mueller-Eckhardt
Journal:  Blut       Date:  1990-07

3.  Platelet-activating factor and phospholipase A2 in patients with septic shock and trauma.

Authors:  J Sörensen; B Kald; C Tagesson; M Lindahl
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

4.  Clinical and experimental studies on the role of platelet-activating factor (PAF) in the pathogenesis of septic DIC.

Authors:  S Ono; S Tamakuma; H Mochizuki; M Kinoshita; Y Ohkusa; S Aosasa; Y Oda; H Ohe
Journal:  Surg Today       Date:  1993       Impact factor: 2.549
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.